Cost-effectiveness of cadonilimab plus chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma
Cadonilimab plus chemotherapy might be a cost-effective regimen when the unit cost of cadonilimab was $151.48 (58% discount) and $188.04 (72% discount) for overall and PD-L1 CPS ⩾ 5 advanced G/GEJ adenocarcinoma.
Authors
- Shunping Li (ORCID: https://orcid.org/0000-0001-8144-6220)
- Lei Dou
- Ziming Wan (ORCID: https://orcid.org/0000-0001-6699-654X)
- Hao Chen (ORCID: https://orcid.org/0000-0002-8400-3780)
- Ruixue Wang (ORCID: https://orcid.org/0000-0002-8772-4954)
- Shixian Liu (ORCID: https://orcid.org/0000-0003-1445-4057)
- Kaixuan Wang (ORCID: https://orcid.org/0009-0006-2221-8256)
Institutions
- Shandong University (CN)
- Shandong Management University (CN)
- Second Hospital of Shandong University (CN)
- Development Research Center (CN)
- Shandong Maternal and Child Health Hospital (CN)
Publication Details
- Journal
- Therapeutic Advances in Gastroenterology
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1177/17562848251366946
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00